The Law Offices of Frank R. Cruz Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Kyverna Therapeutics, Inc. (“Kyverna” or the “Company”) (NASDAQ: KYTX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On or about February 8, 2024, Kyverna conducted its initial public offering (“IPO”), selling 14.5 million shares of common stock for $22.00 per share.

On June 14, 2024, Kyverna provided an update on its lupus nephritis drug, KYV-101, and published an investor presentation disclosing adverse data regarding one of its clinical trials, despite having previously touted patient improvement.

Investors have suffered significant losses since the IPO.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Kyverna securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at 310-914-5007, by email to [e-mail], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241211482483/en/

The Kyverna Therapeutics Stock at the time of publication of the news with a raise of +2,18 % to 4,69USD on Nasdaq stock exchange (11. Dezember 2024, 23:20 Uhr).